Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838502 | 0.87 | KMT2A (0.62) | KMT2AMEN1MAPTIDO1TP53 | |
| SCHEMBL73372 | 0.87 | KMT2A (0.62) | KMT2AMEN1MAPTIDO1TP53 | |
| SCHEMBL3822948 | 0.87 | MAPT (0.81) | KMT2AMEN1MAPTIDO1RXFP1 | |
| SCHEMBL30557433 | 0.87 | MAPT (0.81) | KMT2AMEN1MAPTIDO1RXFP1 | |
| SCHEMBL12585057 | 0.82 | MAPT (0.69) | KMT2AMEN1MAPTIDO1RXFP1 | |
| SCHEMBL13323864 | 0.82 | TAS2R38 (0.60) | KMT2AMEN1MAPTPOLBRAB9A | |
| SCHEMBL171425 | 0.81 | MTNR1A (0.79) | KMT2AMEN1MAPTTP53TSHR | |
| SCHEMBL29875454 | 0.81 | MTNR1A (0.79) | KMT2AMEN1MAPTTP53TSHR | |
| SCHEMBL23220318 | 0.81 | IDO1 (0.68) | KMT2AMEN1MAPTIDO1RXFP1 | |
| SCHEMBL6577711 | 0.80 | RAB9A (0.69) | KMT2AMEN1MAPTIDO1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| US-9624211-B2 | Anti-cancer compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160145250-A1 | ANTI-CANCER COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-26 | — | — | US | disclosed |
| CN-1890248-A | Novel compounds | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145250-A1 | ANTI-CANCER COMPOUNDS | SKP2, TP53, TEAD2 | KMT2A 464/4885MEN1 3204/4885MAPT 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.